BioNano Genomics Inc vs Spotify Technology — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Spotify Technology trades at $488.03 (market cap $103.00B). The key difference: Spotify Technology is far larger — about 7540.3× BioNano Genomics Inc's market cap, and Spotify Technology is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | SPOT | |
|---|---|---|
Market Cap | $13.66M | $103.00B |
Sector | Health | Media |
52-Week High | $4.92 | $738.53 |
52-Week Low | $1.06 | $412.75 |
Enterprise Value | $16.26M | $92.70B |
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Spotify (SPOT) trades at $486.44, down 4.96% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong revenue growth to $17.19B in 2025 and net income of $2.21B, with a record 300 million Premium subscribers in Q2 2026. Recent news highlights Spotify's initiative to label AI-generated artists for transparency, reflecting proactive content management.
The outlook remains positive with a consensus price target of $598.20, implying significant upside. Key risks include rising marketing and AI costs impacting margins, as seen in the Q2 2026 earnings miss. Investor sentiment is buoyed by subscriber growth and monetization efforts, but execution on cost control will be critical for sustained gains.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →